Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Pipeline includes therapies for rare genetic/metabolic diseases (e.g., FCS), placing it in Biotech - Rare Diseases.
|
$8.83B |
$63.85
-3.62%
|
|
BIO
Bio-Rad Laboratories, Inc.
Bio-Rad's Saber Bio antibody discovery platform represents a dedicated platform for high-throughput antibody and T cell receptor discovery.
|
$8.48B |
$313.72
-2.59%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$8.33B |
$71.21
-0.85%
|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT is Blueprint Medicines' flagship oncology/hematology drug; directly produced and marketed, fitting Biotech - Oncology.
|
$8.27B |
$129.46
|
|
KRYS
Krystal Biotech, Inc.
Krystal Biotech's core HSV-1 gene therapy platform and lead product VYJUVEK directly represent a gene therapy business.
|
$8.25B |
$284.63
+0.93%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.22B |
$124.71
-0.32%
|
|
NUVL
Nuvalent, Inc.
Nuvalent is a oncology-focused biotechnology company developing targeted cancer therapies (ROS1/ALK inhibitors), fitting Biotech - Oncology.
|
$7.52B |
$104.26
-1.79%
|
|
CYTK
Cytokinetics, Incorporated
Cytokinetics' core programs target cardiovascular diseases (aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil and ulacamten), making 'Cardiovascular Drugs' the primary investable theme.
|
$7.49B |
$62.58
-1.36%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$7.43B |
$116.92
+0.11%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
GRFS
Grifols, S.A.
Grifols operates as a large, global pharmaceutical company with a core focus on plasma-derived therapies.
|
$7.33B |
$8.89
-0.45%
|
|
HIMS
Hims & Hers Health, Inc.
Peptide therapeutics manufacturing and development capabilities.
|
$7.09B |
$31.43
+0.62%
|
|
GKOS
Glaukos Corporation
Glaukos markets ophthalmic drugs such as iDose TR and corneal health therapies (Photrexa, Epioxa), which are administered to treat eye conditions.
|
$6.90B |
$120.30
+5.08%
|
|
MRUS
Merus N.V.
Company develops multispecific antibody therapeutics for oncology, including lead candidates like petosemtamab and BIZENGRI.
|
$6.81B |
$90.00
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Rhythm's core business is developing and commercializing therapies for ultra-rare diseases (e.g., setmelanotide for MC4R pathway deficiencies, BBS), a hallmark of rare-disease biotech.
|
$6.75B |
$101.67
-4.14%
|
|
PRAX
Praxis Precision Medicines, Inc.
Praxis's Cerebrum platform develops oral small-molecule CNS therapies (e.g., ulixacaltamide, Vormatrigine).
|
$6.68B |
$317.17
+6.52%
|
|
BLCO
Bausch + Lomb Corporation
Ophthalmic Drugs – direct development, licensing, and commercialization of eye-disease medications (e.g., MIEBO, XIIDRA).
|
$6.07B |
$17.18
-1.49%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$6.05B |
$46.60
-3.00%
|
|
STVN
Stevanato Group S.p.A.
Provides Drug Delivery Platforms as integrated containment and delivery solutions for biologics.
|
$5.98B |
$19.79
-5.76%
|
|
PTCT
PTC Therapeutics, Inc.
Sephience PKU and other PTC therapies are oral small-molecule drugs, a major product category for the company.
|
$5.76B |
$72.50
-4.14%
|
|
CDTX
Cidara Therapeutics, Inc.
CD388 is an antiviral small-molecule therapeutic targeting neuraminidase for universal influenza prevention and treatment.
|
$5.61B |
$221.39
+0.00%
|
|
OLED
Universal Display Corporation
Contract research services via Adesis subsidiary.
|
$5.53B |
$116.22
-2.94%
|
|
COGT
Cogent Biosciences, Inc.
Cogent's lead asset bezuclastinib and the described pipeline assets are primarily oral small-molecule tyrosine kinase inhibitors, i.e., Oral Small Molecule Therapeutics.
|
$5.44B |
$38.92
-0.84%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics develops oral, nonpeptide small-molecule therapeutics (lead platform) targeting GPCRs and related pipelines.
|
$5.27B |
$55.97
-0.82%
|
|
ALKS
Alkermes plc
Direct product category encompassing Alkermes' oral small-molecule therapeutics, including LYBALVI.
|
$5.22B |
$31.62
+1.30%
|
|
IBRX
ImmunityBio, Inc.
Lead oncology-focused biotechnology with ANKTIVA and cancer immunotherapy platforms.
|
$5.22B |
$5.54
+40.13%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$5.10B |
$81.96
-3.29%
|
|
GPCR
Structure Therapeutics Inc.
Company focuses on developing oral small-molecule GPCR-targeted therapeutics, including lead GLP-1R agonist and other oral GPCR modulators.
|
$5.10B |
$88.70
+4.33%
|
|
UUUU
Energy Fuels Inc.
Radium/radioisotope recovery plans for targeted alpha therapy isotopes (radiopharmaceuticals).
|
$5.06B |
$21.96
+4.97%
|
|
KYMR
Kymera Therapeutics, Inc.
Kymera's core offering is oral small molecule therapeutics designed to degrade disease-causing proteins (STAT6, IRAK4, IRF5) in immunology indications.
|
$4.97B |
$69.52
-2.25%
|
|
BLTE
Belite Bio, Inc
Lead product Tinlarebant is an ophthalmic drug targeting retinal diseases (STGD1/GA).
|
$4.94B |
$155.06
+3.64%
|
|
CRSP
CRISPR Therapeutics AG
CRISPR-based ex vivo gene-editing therapy CASGEVY is a gene therapy product.
|
$4.87B |
$53.49
-1.32%
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$4.85B |
$30.57
-0.44%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.81B |
$80.80
+0.06%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.58B |
$26.32
+1.21%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$4.57B |
$91.08
-1.34%
|
|
CELC
Celcuity Inc.
Core asset gedatolisib targets oncology indications, placing Celcuity squarely in Biotech - Oncology.
|
$4.54B |
$106.88
+1.52%
|
|
IEP
Icahn Enterprises L.P.
Pharma segment includes global drug development and commercialization activities (eg. Qsiva) typical of Large Cap Pharma companies.
|
$4.48B |
$7.81
-0.64%
|
|
FOLD
Amicus Therapeutics, Inc.
Galafold is an oral pharmacological chaperone and Pombiliti + Opfolda include an oral stabilizer; both are delivered as oral small molecule drugs, making Oral Small Molecule Therapeutics a core product category.
|
$4.42B |
$14.32
+0.07%
|
Showing page 4 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
